DIMIRACETAM

Details

Stereochemistry	RACEMIC
Molecular Formula	C6H8N2O2
Molecular Weight	140.1399
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1CN2C(CCC2=O)N1

InChI

InChIKey=XTXXOHPHLNROBN-UHFFFAOYSA-N

InChI=1S/C6H8N2O2/c9-5-3-8-4(7-5)1-2-6(8)10/h4H,1-3H2,(H,7,9)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24486381
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/8277504 | https://www.ncbi.nlm.nih.gov/pubmed/24898652 | http://adisinsight.springer.com/drugs/800027387

Dimiracetam is a nootropic drug of the racetam family. Dimiracetam inhibited the NMDA-induced increase of [3H]D-Asp release from hippocampal synaptosomes. The increased potency and longer duration of action of dimiracetam, together with the potential cognition enhancing property makes it a very promising and safe for the treatment of neuropathic pain conditions for which there are very limited therapeutic options. Dimiracetam is in Phase II clinical trials for the treatment of HIV-associated pain and in phase I clinical trials for the treatment of osteoarthritis pain.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate NMDA receptor 46 Target ID: CHEMBL1907608 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24486381 \| https://www.pharmacodia.com/yaodu/html/v1/chemicals/f8e480335ca94ffa39015266af2947a8.html	Antagonist 2778		1.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Neuropathic pain 26 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24486381 https://www.ncbi.nlm.nih.gov/pubmed/24898652	Primary		Phase II 1132	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY515179	https://www.001chemical.com/chem/126100-97-8
AA Blocks	AA009HR6	http://www.aablocks.com/goods/Goods/detail?id=AA009HR6
AHH Chemical co.,ltd	MR-1013846	http://www.ahhchemical.com/product/MR-1013846.html
Aaron Chemicals	AR009IIY	http://www.aaronchem.com/126100-97-8
Alichem	69003895	http://www.alichem.com/en/products/126100-97-8.html
Aurora Fine Chemicals LLC	A31.013.147	http://online.aurorafinechemicals.com/info?ID=A31.013.147
BLD Pharm	BD125647	http://www.bldpharm.com/products/126100-97-8.html
Chem Scene	CS-0026742	http://www.chemscene.com/126100-97-8.html
ChemShuttle	182368	http://www.chemshuttle.com/catalogsearch/result/?q=126100-97-8&cat=
Chemspace	CSSB00000076864	https://chem-space.com/CSSB00000076864
MolPort	MolPort-038-354-205	https://www.molport.com/shop/molecule-link/MolPort-038-354-205
Molcore	MC515179	https://www.molcore.com/product/126100-97-8
MuseChem	M109243	https://www.musechem.com/product/M109243.html
Smolecule	S526207	http://www.smolecule.com/products/s526207
Synblock Inc	SB17242	http://www.synblock.com/product/126100-97-8.html
THE BioTek	bt-265115	https://www.thebiotek.com/product/inhibitors/bt-265115
abcr GmbH	AB513006	http://www.abcr.com/shop/en/AB513006
eNovation Chemicals	D677371	https://www.enovationchem.com/ProductDetails.asp?ProductID=D677371
eNovation Chemicals	D762244	https://www.enovationchem.com/ProductDetails.asp?ProductID=D762244

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

400 mg b.i.d. and doubling the dose every two weeks until a maximum of 1600 mg b.i.d. (8 weeks treatment).

Route of Administration: Oral

In Vitro Use Guide

Dimiracetam proved to be even more potent in the spinal cord, as the NMDA-induced increase of [3H]D-Asp release was already completely abolished at 1 uM.

Name

Type

Language

DIMIRACETAM

Official Name

English

NT-11624

Code

English

1H-PYRROLO(1,2-A)IMIDAZOLE-2,5(3H,6H)-DIONE, DIHYDRO-

Systematic Name

English

(±)-DIHYDRO-1H-PYRROLO(1,2-A)IMIDAZOLE-2,5(3H,6H)-DIONE

Systematic Name

English

DIHYDRO-1H-PYRROLO(1,2-A)IMIDAZOLE-2,5(3H,6H)-DIONE

Systematic Name

English

dimiracetam [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1509